Biosimilar versions of Humira (adalimumab) are available, offering alternatives to the originator drug for certain conditions. These biosimilars are highly similar to Humira in terms of safety, purity, and potency, and are approved for the same indications [1].
What are the Humira biosimilars available?
Several biosimilars to Humira have received FDA approval. These include adalimumab-atto (Amjevita), adalimumab-yfgn (Abrilada), adalimumab-aqzu (Hulio), adalimumab-zbkx (Hadlima), and adalimumab-adaz (Hyrimoz) [2]. Other biosimilars are also available in different markets [3].
How do biosimilars work?
Biosimilars are approved based on a rigorous scientific and regulatory review process, demonstrating that they are highly similar to the reference product and have no clinically meaningful differences in safety, purity, and potency [1]. They work by targeting the same biological pathways as Humira, such as blocking tumor necrosis factor-alpha (TNF-alpha), which plays a role in inflammation [4].
When did Humira biosimilars become available?
The first biosimilars for Humira began launching in the United States in 2023 [2]. Exclusivity and patent cliffs for the originator drug have paved the way for these market entries [5].
How do Humira biosimilars compare to the original drug?
Biosimilars are not interchangeable with the reference product unless designated as such by the FDA. While they are highly similar, minor differences in inactive ingredients are permitted. Prescribers and pharmacists consider these factors when choosing a treatment [1].
What are the potential cost savings with Humira biosimilars?
The availability of biosimilars is expected to increase competition, potentially leading to lower prices and increased patient access to treatment for conditions like rheumatoid arthritis, psoriatic arthritis, and Crohn's disease [1][3].
Who manufactures these Humira biosimilars?
Manufacturers of approved Humira biosimilars include Amgen (Amjevita), Pfizer (Abrilada), Samsung Bioepis (Hulio), Samsung Bioepis (Hadlima), and Sandoz (Hyrimoz) [2].
What is the patent situation for Humira?
Humira has faced extensive patent litigation and challenges, with numerous patents related to its formulation, manufacturing, and use. This complex patent landscape has influenced the timeline for biosimilar market entry [5].
What are the next steps for biosimilar competition?
As more biosimilars enter the market, further price reductions and broader adoption are anticipated. The FDA continues to evaluate and approve biosimilar applications, expanding treatment options for patients [1][3].
Sources:
[1] https://www.fda.gov/drugs/biosimilars/about-biosimilars
[2] https://www.drugpatentwatch.com/blog/humira-biosimilars-us-launch-guide
[3] https://www.drugpatentwatch.com/adalimumab
[4] https://www.drugpatentwatch.com/blog/what-is-adalimumab-and-how-does-it-work
[5] https://www.drugpatentwatch.com/blog/humira-patent-landscape-explained